# Siolta Therapeutics: Research, San Carlos, United States

> Siolta Therapeutics: Siolta Therapeutics, Inc. Based in San Carlos, United States. Founded 2016. What Millionrounds holds on them, and what we have not seen.

Source: https://millionrounds.com/startup/siolta-therapeutics (Millionrounds; every figure on the page links to its filing or article)

United States · [Research startup](https://millionrounds.com/companies)

# Siolta Therapeutics

Siolta Therapeutics, Inc.

Funding reported Last round: Series C

Research San Carlos, United States

Company summary

- **Founded:** 2016 10 years old
- **Team:** 15 11 to 50 people
- **Funding reported:** $42M in dollars
- **Last round:** Series C Mar 2024

How sure we are

- ✓ **Listed** We know it exists and what it does
- 2 **Funding reported** A company dataset reports a raise
- 3 **Observed** A filing or a dated announcement confirms a round

No round for Siolta Therapeutics has been confirmed by a filing or an announcement yet, so nothing here counts toward an investor's record. [How we decide](https://millionrounds.com/methodology)

## About Siolta Therapeutics

Siolta Therapeutics, Inc.

is a clinical-stage biopharmaceutical company based in San Carlos, California, founded in 2016. The company specializes in developing live biotherapeutic products (LBPs) derived from the human microbiome, aiming to address chronic inflammatory diseases. Co-founded by Dr. Nikole Kimes and Dr. Susan Lynch, Siolta leverages their expertise in microbiology and immunology to create innovative microbiome-based therapies. The company's flagship offering is the Precision Symbiotics PlatformTM, which integrates clinical data, bioinformatics, and microbial science to engineer bacterial consortia targeting specific disease mechanisms. Siolta also maintains in-house Good Manufacturing Practice (GMP) facilities to ensure high-quality production of its microbial products. Its lead product, STMC-103H, is in Phase 2 clinical development for preventing atopic diseases in at-risk newborns, with a focus on conditions like atopic dermatitis, food allergies, and asthma. Siolta Therapeutics is committed to redefining treatment approaches by emphasizing prevention and restoration through microbiome health.

## What company datasets say Siolta Therapeutics raised

Funding, as reported

Reported in all **$42M** in dollars

Rounds **5**

Last round **Series C**

Last round size **$12M**

Last round date **Mar 2024**

Investors listed **8**

## Founders and team

From Siolta Therapeutics's own website: 2 founders, 5 on the team.

**Nikole Kimes PhD** Founder and Chief Executive Officer

**Susan Lynch PhD** Founder and Board of Directors

- **Ricardo Valladares PhD** Chief Scientific Officer
- **Alison Vrbanac PhD** Senior Scientist - Bioinformatics Lead
- **Andrew H. Kim PhD** Senior Scientist - Bioinformatics
- **Kevin Foley PhD** Senior Scientist
- **Neeraja Vajrala PhD** Director of Microbiology

Advisers *Clifford Samuel* *John C. Martin* *Matthew Meyer*

## The company, in detail

What they build

Known for

health care in vitro screening in vivo screening immune system regulation biotechnology research manufacturing pharmaceutical development maternal microbiome microbiome safety clinical trials ecosystem approach microbiome-based therapies microbiota restoration pediatric microbiome microbial formulation hospital & health care microbial ecology

Built with from their website

Google Tag Manager WordPress.org PWA Apache Google Workspace Viewport Meta Apple Business Manager Google Meet Priority Hints Google Font API

+8 more

MySQL Mobile Friendly Mapbox Open Graph jQuery RSS Yoast SEO Yoast

- **Sector:** Research
- **Industry code:** NAICS 541714, SIC 2834, 8731, 2836
- **Region:** California
- **Revenue:** $1.2M a year, as listed
- **Full record:** [Every detail in the company directory](https://millionrounds.com/directory/siolta-therapeutics)

## Research in United States

Startups like it

- [**OpenAI** San Francisco · founded 2011 *Raised*](https://millionrounds.com/company/openai)
- [**Retro Biosciences** Redwood City · founded 2021 *Raised*](https://millionrounds.com/company/retro-biosciences)
- [**NewLimit** South San Francisco · founded 2022 *Raised*](https://millionrounds.com/company/newlimit)
- [**Pathos** New York · founded 2022 *Raised*](https://millionrounds.com/company/pathos)
- [**Colossal Biosciences** Dallas · founded 2021 *Raised*](https://millionrounds.com/company/colossal-biosciences)
- [**Oratomic** South Pasadena *Raised*](https://millionrounds.com/company/oratomic)
- [**Beeline Medicines** Stamford · founded 2025 *Raised*](https://millionrounds.com/company/beeline-medicines)
- [**Element Biosciences** San Diego · founded 2017 *Raised*](https://millionrounds.com/company/element-biosciences)

## Is this your company?

Add your raise, your deck and your story, and put Siolta Therapeutics in front of investors. Or tell us what we have wrong.

[List your startup](https://millionrounds.com/list-your-startup)[Send a correction](https://millionrounds.com/corrections)